121 related articles for article (PubMed ID: 32552950)
21. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis.
Barnes JA; Lacasce AS; Feng Y; Toomey CE; Neuberg D; Michaelson JS; Hochberg EP; Abramson JS
Ann Oncol; 2011 Aug; 22(8):1859-64. PubMed ID: 21339382
[TBL] [Abstract][Full Text] [Related]
22. Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study.
Rigaud C; Auperin A; Jourdain A; Haouy S; Couec ML; Aladjidi N; Gandemer V; Lambliotte A; Plat G; Landman-Parker J; Michon J; Leblanc T; Patte C; Minard-Colin V
Pediatr Blood Cancer; 2019 Sep; 66(9):e27873. PubMed ID: 31207026
[TBL] [Abstract][Full Text] [Related]
23. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study.
Mead GM; Sydes MR; Walewski J; Grigg A; Hatton CS; Pescosta N; Guarnaccia C; Lewis MS; McKendrick J; Stenning SP; Wright D;
Ann Oncol; 2002 Aug; 13(8):1264-74. PubMed ID: 12181251
[TBL] [Abstract][Full Text] [Related]
24. [Clinical and prognostic analysis of 186 children with Burkitt's lymphoma].
Zhang M; Jin L; Yang J; Duan YL; Huang S; Zhou CJ; Zhang YH
Zhonghua Er Ke Za Zhi; 2018 Aug; 56(8):605-610. PubMed ID: 30078243
[No Abstract] [Full Text] [Related]
25. [Efficacy of Hyper-CVAD/MA and CHALL-01 regimens in the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia patients under 60 years old].
Huang AJ; Wang LB; Du J; Tang GS; Cheng H; Gong SL; Gao L; Qiu HY; Ni X; Chen J; Chen L; Zhang WP; Wang JM; Yang JM; Hu XX
Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):625-632. PubMed ID: 31495127
[No Abstract] [Full Text] [Related]
26. Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children.
Spreafico F; Massimino M; Luksch R; Casanova M; Cefalo GS; Collini P; Ferrari A; Polastri D; Terenziani M; Gasparini M; Fossati-Bellani F
J Clin Oncol; 2002 Jun; 20(12):2783-8. PubMed ID: 12065554
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
[TBL] [Abstract][Full Text] [Related]
28. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome.
Choi KA; Lee JE; Kim YG; Kim DJ; Kim K; Ko YH; Oh HY; Kim WS; Huh W
Ann Hematol; 2009 Jul; 88(7):639-45. PubMed ID: 19030857
[TBL] [Abstract][Full Text] [Related]
30. Outcome of children with B cell lymphoma in Venezuela with the LMB-89 protocol.
Acquatella G; Insausti CL; García R; Gómez R; Hernández M; Carneiro M; Santos S; Nouel A
Pediatr Blood Cancer; 2004 Oct; 43(5):580-6. PubMed ID: 15382276
[TBL] [Abstract][Full Text] [Related]
31. Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea.
Choi MK; Jun HJ; Lee SY; Kim KH; Lim DH; Kim K; Ko YH; Kim WS; Kim SJ
Ann Hematol; 2009 Nov; 88(11):1099-106. PubMed ID: 19288103
[TBL] [Abstract][Full Text] [Related]
32. A 5-drug regimen maximizing the dose of cyclophosphamide is effective therapy for adult Burkitt or Burkitt-like lymphomas.
Kujawski LA; Longo WL; Williams EC; Turman NJ; Brandt N; Mosher DF; Eickhoff JC; Kahl BS
Cancer Invest; 2007 Mar; 25(2):87-93. PubMed ID: 17453819
[TBL] [Abstract][Full Text] [Related]
33. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma.
Ritchie DS; Seymour JF; Grigg AP; Roberts AW; Hoyt R; Thompson S; Szer J; Prince HM
Ann Hematol; 2007 Feb; 86(2):101-5. PubMed ID: 17089127
[TBL] [Abstract][Full Text] [Related]
34. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
Romaguera JE; Fayad L; Rodriguez MA; Broglio KR; Hagemeister FB; Pro B; McLaughlin P; Younes A; Samaniego F; Goy A; Sarris AH; Dang NH; Wang M; Beasley V; Medeiros LJ; Katz RL; Gagneja H; Samuels BI; Smith TL; Cabanillas FF
J Clin Oncol; 2005 Oct; 23(28):7013-23. PubMed ID: 16145068
[TBL] [Abstract][Full Text] [Related]
35. Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine.
Inamdar KV; Romaguera JE; Drakos E; Knoblock RJ; Garcia M; Leventaki V; Medeiros LJ; Rassidakis GZ
Cancer; 2009 Oct; 115(20):4727-36. PubMed ID: 19708031
[TBL] [Abstract][Full Text] [Related]
36. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
37. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine.
Garcia M; Romaguera JE; Inamdar KV; Rassidakis GZ; Medeiros LJ
Cancer; 2009 Mar; 115(5):1041-8. PubMed ID: 19170236
[TBL] [Abstract][Full Text] [Related]
38. [Rituximab combined with short-course and intensive regimen for Burkitt leukemia: efficacy and safety analysis].
Li Y; Gong XY; Zhao XL; Wei H; Wang Y; Lin D; Zhou CL; Liu BC; Wang HJ; Li CW; Li QH; Gong BF; Liu YT; Wei SN; Zhang GJ; Mi YC; Wang JX; Liu KQ
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):502-505. PubMed ID: 32654465
[No Abstract] [Full Text] [Related]
39. Burkitt lymphoma in children: the Israeli experience.
Eldar AH; Futerman B; Abrahami G; Attias D; Barak AB; Burstein Y; Dvir R; Gabriel H; Horovitz J; Kapelushnik J; Kaplinsky H; Miskin H; Sthoeger D; Toren A; Vilk-Revel S; Weintraub M; Yaniv I; Linn S; Arush MB
J Pediatr Hematol Oncol; 2009 Jun; 31(6):428-36. PubMed ID: 19648792
[TBL] [Abstract][Full Text] [Related]
40. Clinical profile, outcome and challenges in the management of pediatric Burkitt lymphoma: a single center experience.
Chauhan P; Gupta A; Mandelia A; Yadav S; Rahman K; Nityanand S
Pediatr Hematol Oncol; 2021 May; 38(4):305-318. PubMed ID: 33646922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
